We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $107.96 · 24 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Incyte (INCY) Monjuvi Shows Promise as First-Line Treatment for Lymphoma - GuruFocus
Incyte (INCY) Monjuvi Shows Promise as First-Line Treatment for Lymphoma GuruFocus
Incyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trial - Seeking Alpha
Incyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trial Seeking Alpha
Incyte says Frontmind trial shows 25% reduction in disease progression or death in high-risk DLBCL - marketscreener.com
Incyte says Frontmind trial shows 25% reduction in disease progression or death in high-risk DLBCL marketscreener.com
Incyte Says Frontmind Trial Shows 25% Reduction In Disease Progression Or Death In High-Risk Dlbcl - TradingView
Incyte Says Frontmind Trial Shows 25% Reduction In Disease Progression Or Death In High-Risk Dlbcl TradingView
Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate By Reuters - Investing.com
Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate By Reuters Investing.com
Incyte drug combo cuts risk of high-risk lymphoma worsening by 25% - Stock Titan
Incyte drug combo cuts risk of high-risk lymphoma worsening by 25% Stock Titan
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 28. | After market close (AMC) | $1.82 | — | — | $1.37B | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $0.8 | — | — | $1.05B | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-0.8 | — | — | $3.06B | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-1.24 | — | — | $1.92B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 22. | Bernstein | — | Initiate coverage | — → Market Perform | — | Bernstein: Market Perform |
| 2026. 05. 21. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 05. 04. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 04. 30. | Oppenheimer | — | Maintain | Perform → Perform | — | Oppenheimer: Perform |
| 2026. 04. 29. | Stifel | — | Maintain | Buy → Buy | — | Stifel: Buy |
| 2026. 04. 15. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 415,914 | $39.15B | 0.03% | — | New position |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 168,763 | $15.88B | 0.03% | — | New position |
| 3 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 36,749 | $3.63B | 0.01% | — | New position |